Sesen Bio Board Unanimously Recommends All Stockholders to Vote “FOR” the Value Maximizing Merger on the WHITE Proxy Card Today CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) ...
Sesen Bio (NASDAQ:SESN) investors reiterated their plan to vote against the merger with Carisma Therapeutics, calling it an "illogical, value-destructive" deal. Sesen rose 4.2%. Bradley L. Radoff and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today announced that Institutional Shareholder Services ...
In the third quarter of 2022 results,we expect investors to focus onSesen Bio’s SESN near-term strategic priorities to maximize shareholder value and the development of its pipeline candidates. Sesen ...
Clinical-stage biotech Sesen Bio (NASDAQ:SESN) announced Thursday that its shareholders greenlighted the company’s pending merger with Carisma Therapeutics at a special meeting of stockholders held ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min An investor group holding 8.4% ...
About four months after starting its search for strategic alternatives, Sesen Bio Inc. disclosed an all-stock merger with privately held cell-therapy specialist Carisma Therapeutics Inc., a move that ...
Investors in Sesen Bio, Inc. SESN need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 18, 2022 $2.00 Call had some of the highest implied ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results